Investigating kidney disease risk linked to specific genetic variants in African Americans
Human iPSC-derived Podocytes to Study APOL1 High-Risk Variants
['FUNDING_FELLOWSHIP'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10906647
This study is looking at how specific changes in a gene called APOL1 might lead to kidney problems, especially in African Americans, by using special lab-grown cells to see how these changes affect important kidney cells, which could help find new ways to treat kidney disease.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10906647 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how certain genetic variants in the APOL1 gene contribute to kidney disease, particularly in the African American population. By using human-induced pluripotent stem cells (iPSCs) that have been genetically modified to carry these variants, researchers aim to study the mechanisms that lead to kidney damage. The project will explore how these genetic factors affect podocytes, the cells crucial for kidney filtration, and how their depletion impacts kidney function. This work could provide insights into potential new treatments for chronic kidney disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals of African descent, particularly those with a family history of kidney disease or who carry the APOL1 high-risk variants.
Not a fit: Patients without the APOL1 high-risk variants or those with kidney disease due to other causes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and potentially new treatments for chronic kidney disease, particularly for those at higher genetic risk.
How similar studies have performed: Previous research has shown that understanding genetic factors in kidney disease can lead to significant advancements in treatment, suggesting this approach has potential for success.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAINES, LAUREN ELIZABETH — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: HAINES, LAUREN ELIZABETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus